Ticker AIM – AIM ImmunoTech – sales, description, marketcap – Tickerday.com

AIM

AIM ImmunoTech

AIM ImmunoTech Inc. (AMEX: AIM), formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida. Founded in 1990, the company has 32 employees.

Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 84.14M; Volume: 159.51K; AvgVol 3m: 5.70M; Beta: -0.97;

Cost estimate:

P/E: ; EPS: -1.49; EPS growth quarter/prev quarter: 89.50%;

EPS growth this year: 73.20%; EPS growth past 5 years: 44.30%;

EPS ttm: -1.49;

P/S: 433.61; P/B: 1.49; P/Cashflow: 2.48; P/FCF: ;

Sales: 190.00K; Sales growth quarter/prev quarter: 37.90%; Sales growth past 5 years: -6.60%;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -33.40%; ROE – return on equity: -42.70%; LT Debt/Equity: 0.04; Total Debt/Equity: 0.05;

Dividend: ; Dividend Yield (%): ;

Insider Ownership: 0.50%; Insider Transactions:13.86%;

Institutional Ownership: 4.70%; Institutional Transactions: 295.63%;

Data update: 07.10.2020.

Leave a comment

Your email address will not be published. Required fields are marked *